HIV treatment can stop transmission of the virus from mothers to their babies. But how do you ensure all women are retained on treatment and so benefit? Six studies carried out by the WHO in Africa recruited more than 5000 pregnant women. They provided hard evidence that peer support by “Mentor” and “Expert” mothers significantly helps with retention.
Every year an estimated million people die of HIV related illness, despite the availability of very effective treatment. The highest death rate is among patients who seek treatment very late. The REALITY Trial showed how giving this group extra prophylaxis medicines could save many lives.
The story of a small Malawian boy, whose life has been changed by the replacement of syrups and adult pills with baby pills which are far better adapted for use in an African village. The pills were developed by CIPLA and tested in the CHAPAS trials.
A film project to provoke debate in Communities and Schools, where the story is told entirely from the perspective of a brave girl growing up with HIV in Harare. The film is built around, ZENITH, a Wellcome Trust funded research project looking at HIV prevalence of young people in Harare, and improving community care..
More than 2.6 million stillbirths occur globally every year with very slow progress being made to tackle this ‘silent problem’, according to research published in The Lancet. This film tells the stories of two women, in the UK and Malawi, and their common search to come to terms with the stillbirth of a baby.
These films tells the story of a major clinical trial in Africa which contradicted twenty years of clinical practice in the developed world using IV fluid resuscitation for children with febrile shock. It shows clearly why Randomized Controlled Trails are the gold standard for evidence.
DART and ARROW Clinical Trials: HIV priorities for Africa. How important is monitoring HIV treatment with routine laboratory tests?
This set of films tell the stories of two major Clinical Trials which pioneered the roll-out of HIV treatment in Africa. They are built around the moving stories of trial participants, many of whom were close to death when they joined and were the first in their communities to receive Anti-Retroviral Therapy (ART). The results of the trials strongly suggest that rollout of ARVs should have been a much higher priority than investing in expensive routing lab testing, especially in rural areas with no labs..